文献速递血管炎

一种新型无糖皮质激素维持方案治疗ANCA相关性血管炎

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究纳入49例活动性MPO-或PR3-ANCA血管炎或ANCA阴性寡免疫肾小球肾炎患者,采用利妥昔单抗两剂、3个月低剂量环磷酰胺及1-2周口服糖皮质激素的诱导方案。所有患者均达到缓解,总体结局与EUVAS试验匹配队列相当,但环磷酰胺和糖皮质激素总暴露量更低(P < 0.001),严重感染率低于RITUXVAS试验(P = 0.02)。

要点

  • 早期快速撤减糖皮质激素方案在严重AAV中诱导缓解有效。
  • 该方案环磷酰胺和糖皮质激素总暴露量显著低于EUVAS试验匹配队列(P < 0.001)。
  • 严重感染率低于RITUXVAS试验(P = 0.02),首年无新发糖尿病。

核心结论

  • 在严重AAV中早期撤减糖皮质激素诱导缓解与标准治疗同样有效,且糖皮质激素相关不良事件减少。

研究设计与样本

  • 纳入49例活动性MPO-或PR3-ANCA血管炎或ANCA阴性寡免疫肾小球肾炎患者,46例随访至少12个月。
  • 诱导治疗包括两剂利妥昔单抗、3个月低剂量环磷酰胺及1-2周口服糖皮质激素。

主要发现

  • 所有患者均达到缓解,肌酐、蛋白尿、CRP、ANCA水平和BVAS均下降。
  • 3例就诊时需透析的患者变为透析非依赖。
  • 2例患者因血管炎需要引入维持性糖皮质激素。
  • 总体结局与两个匹配队列(n = 172)相当,但环磷酰胺和糖皮质激素总暴露量更低(P < 0.001)。
  • 严重感染率低于RITUXVAS试验(P = 0.02),首年无新发糖尿病,历史EUVAS试验率为8.2%(P = 0.04)。

临床怎么用

  • 对于严重AAV患者,可考虑采用早期快速撤减糖皮质激素的诱导方案以减少糖皮质激素暴露及相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Glucocorticoids (GCs) are a mainstay of treatment for patients with ANCA-associated vasculitis (AAV) but are associated with significant adverse effects. Effective remission induction in severe AAV using extremely limited GC exposure has not been attempted. We tested an early rapid GC withdrawal induction regimen for patients with severe AAV. METHODS: Patients with active MPO- or PR3-ANCA vasculitis or ANCA-negative pauci-immune glomerulonephritis were included. Induction treatment consisted of two doses of rituximab, 3 months of low-dose CYC and a short course of oral GC (for between 1 and 2 weeks). Clinical, biochemical and immunological outcomes as well as adverse events were recorded. RESULTS: A total of 49 patients were included, with at least 12 months of follow-up in 46. All patients achieved remission, with decreases observed in creatinine, proteinuria, CRP, ANCA level and BVAS. Three patients requiring dialysis at presentation became dialysis independent. Two patients required the introduction of maintenance GC for treatment of vasculitis. Overall outcomes were comparable to those of two matched cohorts (n = 172) from previous European Vasculitis Society (EUVAS) trials, but with lower total exposure to CYC and GCs (P < 0.001) and reduced rates of severe infections (P = 0.02) compared with the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial. We found no new cases of diabetes in the first year compared with historic rates of 8.2% from the EUVAS trials (P = 0.04). CONCLUSION: Early GC withdrawal in severe AAV is as effective for remission induction as the standard of care and is associated with reduced GC-related adverse events.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pepper RJ, McAdoo SP, Moran SM, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019. PMID: 30239910. doi:10.1093/rheumatology/key288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。